GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up

Background: GOLFIG is a chemo-immunotherapy regimen established in preclinical models that combines gemcitabine + FOLFOX (fluoropyrimidine backbone coupled to oxaliplatin) poly-chemotherapy with low-dose s. c. recombinant interleukin-2 (rIL-2) and granulocyte-macrophage colony stimulating factor (GM...

詳細記述

書誌詳細

出版年:	Frontiers in Oncology
主要な著者:	Michele Caraglia, Pierpaolo Correale, Rocco Giannicola, Nicoletta Staropoli, Cirino Botta, Pierpaolo Pastina, Antonello Nesci, Nadia Caporlingua, Edoardo Francini, Laura Ridolfi, Enrico Mini, Giandomenico Roviello, Domenico Ciliberto, Rita Maria Agostino, Alessandra Strangio, Domenico Azzarello, Valerio Nardone, Antonella Falzea, Salvatore Cappabianca, Marco Bocchetti, Graziella D'Arrigo, Giovanni Tripepi, Pierfrancesco Tassone, Raffaele Addeo, Antonio Giordano, Luigi Pirtoli, Guido Francini, Pierosandro Tagliaferri
フォーマット:	論文
言語:	英語
出版事項:	Frontiers Media S.A. 2019-11-01
主題:	colorectal cancer metastatic chemotherapy immunotherapy GOLFIG phase III clinical trial
オンライン･アクセス:	https://www.frontiersin.org/article/10.3389/fonc.2019.01102/full